Navigation Links
Cytos Biotechnology Reports Results from Phase IIa Study with,CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

the treatment of allergic diseases. It consists of the Immunodrug™ QbG10 which is comprised of the virus-like particle Qb filled with a synthetic immunostimulatory DNA sequence called G10. CYT003-QbG10 is designed as a disease-modifying treatment and aims to induce a potent Th1 type immune response in order to suppress an “allergic” Th2 type immune response. An open-label phase IIa study with CYT003-QbG10 combined with an allergen extract of house dust mites at a standard dose showed excellent longterm efficacy in patients allergic to dust mites. Furthermore, two placebo-controlled phase IIa
studies with CYT003-QbG10 monotherapy delivered positive results in patients suffering from grass pollen and house dust mite allergy.

For further information please contact: Cytos Biotechnology AG, Wagistrasse 25, CH-8952 Schlieren (Zurich)
Dr. Claudine Blaser
Director Corporate Communications
Phone: +41 44 733 47 20
Fax: +41 44 733 47 18
e-Mail: claudine.blaser@cytos.com
Website: www.cytos.com

About Cytos Biotechnology
Cytos Biotechnology AG is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™. Immunodrugs™ are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs™ are designed to instruct the patient’s immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its Immunodrug™ platform, Cytos Biotechnology has built a full pipeline of different Immunodrug™ candidates in various disease areas, of which 6 are currently in clinical developm
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for the Treatment of Psoriasis
2. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
3. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Prana Biotechnology Presents New Key Findings on PBT2
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
7. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
8. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
9. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
Post Your Comments:
(Date:3/27/2015)... , March 27, 2015   Hospira, ... leader in biosimilars and the world,s leading provider ... studies that support an evaluation of biosimilarity of ... Food and Drug Administration (FDA) conditionally approved name ... EPOGEN™ (epoetin alfa). These study data were presented ...
(Date:3/27/2015)... , March 27, 2015  Delcath Systems, ... and medical device company focused on oncology with ... metastatic liver cancers, announces the reporting of data ... Melphalan Hydrochloride for Injection with the Delcath Hepatic ... poster presentation at the Society of Surgical Oncology ...
(Date:3/26/2015)... WOODBRIDGE, ON , March 26, 2015 /PRNewswire/ - Pivotal ... specialty pharmaceutical company with a focus on Omega-3 therapies ... March 25, 2015 it issued 763,752 common shares of ... payment of interest for the period of December 5 ... on its outstanding Convertible Notes that is due on ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... 16, 2011 DecisionView Inc., a leading provider ... for life sciences companies, today announced that a ... Roche have agreed to participate in the creation ... based on real-world clinical performance data. Each of ...
... N.J., June 16, 2011 Ferring Pharmaceuticals Inc. proudly ... Houston in an effort to help increase awareness about ... of healthy aging. The NSG is ... and is organized by the National Senior Games Association, ...
Cached Medicine Technology:DecisionView to Create Clinical Trial Enrollment Benchmarks 2DecisionView to Create Clinical Trial Enrollment Benchmarks 3Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 2Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 3Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 4
(Date:3/29/2015)... North American Seminars receives Texas Board Physical ... Courses . , Utilizing Pilates to Enhance ... approval # 56399TX      , The Interactive Shoulder ... - 10.5 hours - Texas Board of Physical Therapy ... of the SI Joint - 10 hours - Texas ...
(Date:3/28/2015)... Tucson, AZ. (PRWEB) March 28, 2015 ... according to a new study by researchers ... (HSPH). , Produced with the support of the Coffee ... the journal Molecular Psychiatry this past fall, the study—one ... a meta-analysis of genomic data from more than 120,000 ...
(Date:3/28/2015)... York, New York (PRWEB) March 28, 2015 ... http://www.vaginalmeshlawsuit2015.com/ ) involving devices manufactured by C.R. Bard, ... litigation underway in U.S. District Court, Southern District ... S. Grand, is serving on the Plaintiffs’ Steering ... 24th, the Court has granted certain defendants named ...
(Date:3/28/2015)... 2015 An article in Fortune on ... prove critical to organizations that deal with PCI (Payment ... of data security, is worsening . Using numbers ... every major category out of the twelve measured improved, ... all the craziness that has gone on in the ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... injuries is a growing field in orthopaedic medicine. While ... labral tear to confirm the pain etiology, research presented ... ( AOSSM ) Specialty Day suggests that pain relief ... following arthroscopic hip surgery. , “Our study looked ...
Breaking Medicine News(10 mins):Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2
... Streamline Health Solutions, Inc. (Nasdaq: STRM ) today announced the financial ... , , Highlights of the quarter and the nine-month ... Revenues increased 11% versus comparable quarter in the previous year; , ... , Year-to-date company has won 8 total new ...
... role in immune, inflammatory processes, study says , , ... have higher levels of the obesity-related hormone leptin than ... study included 77 psoriasis patients and a control group ... researchers gathered health information about the participants and analyzed ...
... Dec. 15 Following is a statement from Michael ... in regards to its financial exposure with Madoff Securities: ... Health System,s financial exposure with Madoff Securities is limited to ... who stipulated that the funds be invested with Madoff. The ...
... footwear choices, properly moisturizing can soothe holiday soles. , ... Bethesda, MD ... an extra boost of holiday cheer, the same winter weather that puts ... fierce toll on their feet. , , , , ,“Foot ailments ...
... for delivering,albuterol, a fast-acting bronchial dilator, currently use propellants ... beginning December 31st,2009, or replacement HFA,s. Both propellants are ... at near-supersonic speeds. , ... stream of air by ejecting,the medication from a microfluidic ...
... of all Californians under age 65 were without health insurance ... brief released today by the UCLA Center for Health Policy ... data from the California Health Interview Survey (CHIS), the policy ... insurance coverage for all or some of 2007, the most ...
Cached Medicine News:Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 2Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 3Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 4Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 5Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 6Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 7Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 8Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 9Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 10Health News:Streamline Health Solutions, Inc. Reports Third Quarter Results 11Health News:Obesity-Related Hormone Tied to Psoriasis 2Health News:North Shore-LIJ Health System Exposure With Madoff Securities Limited to $5.7M 2Health News:‘Tis The Season to Avoid Foot Follies: Tips to Keep You on Your Feet 2Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 2Health News:Next Safety Develops an Air-Based Asthma Medication Inhaler That Does Not Use a Refrigerant Propellant 3Health News:Nearly 6.4 million Californians lack health insurance, report shows 2
... Photosilk Plus offers a new and efficient ... medicine treatments. Springing from ongoing research and ... is not just a light source, but ... Photosilk Plus represents new horizons in pulsed-light-based ...
Auto Refkeratomoeter...
The convenience of safe and precise Patient Controlled Analgesia in a flexible system designed with advanced technology. This is progressive, innovative, and effective pain management in a sophistica...
Pain management can be complicated. But that doesn't mean your PCA infusion system should be. The new SYNDEO PCA Syringe Pump streamlines pain therapy with a powerful combination of intelligent desig...
Medicine Products: